MedTrace Logo

Terlipressin Administration in Patients Undergoing Major Liver Resection

NCT01921985 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2018-03-29

No results posted yet for this study

Summary

This study investigates if the administration of terlipressin reduces complications after major liver surgery.

Conditions

  • Liver Resection
  • Liver Failure

Interventions

DRUG

Terlipressin

Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).

DRUG

Placebo

Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Guido Beldi, Professor Dr. med. · University of Bern

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01921985 on ClinicalTrials.gov